1-(4-methylpyridin-2-yl)propan-1-one

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(4-methylpyridin-2-yl)propan-1-one
• 英文别名: 1-(4-methyl-pyridin-2-yl)-propan-1-one；1-(4-methylpyridin-2-yl)-propan-1-one
• 化学式: C₉H₁₁NO
• 分子量: 149.192
• InChiKey: OFTSDRMALRIGMV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(4-methylpyridin-2-yl)propan-1-one 在 磺酰氯 作用下， 以 氯仿 为溶剂， 生成 2-氯-1-(4-甲基-2-吡啶基)-1-丙酮
  参考文献：
  名称：

  Pyridine compounds and their pharmaceutical use

  摘要：

  根据所附的规格说明书，本发明的化合物(I)和药用可接受的盐具有强烈的抑制一氧化氮(NO)生成的活性，并且可用于预防或治疗由NOS（一氧化氮合酶）介导的疾病，例如成人的呼吸窘迫综合征、心肌炎、滑膜炎、败血症休克、胰岛素依赖型糖尿病、溃疡性结肠炎、脑梗塞、类风湿性关节炎、骨关节炎、骨质疏松症、系统性红斑狼疮、器官移植排斥反应、哮喘、疼痛、溃疡等人类和动物的疾病。

  公开号：

  US06521643B1
• 作为产物：
  描述：

  2-氰基-4-甲基吡啶 、 乙基溴化镁 在 盐酸 作用下， 以 乙醚 、 水 为溶剂， 反应 3.25h， 以77%的产率得到1-(4-methylpyridin-2-yl)propan-1-one
  参考文献：
  名称：

  手性铱配合物通过可见光活化光氧化还原催化对映选择性催化三氯甲基化

  摘要：

  报道了 2-酰基咪唑和 2-酰基吡啶的对映选择性催化三氯甲基化。几种产品形成对映体过量≥99%。在该系统中，手性铱配合物具有双重功能，既作为具有催化活性的手性路易斯酸，又作为原位组装的可见光触发光氧化还原催化剂的前体。

  DOI：

  10.1021/jacs.5b06010

文献信息

• Enantioselective, Catalytic Trichloromethylation through Visible-Light-Activated Photoredox Catalysis with a Chiral Iridium Complex
  作者：Haohua Huo、Chuanyong Wang、Klaus Harms、Eric Meggers

  DOI：10.1021/jacs.5b06010

  日期：2015.8.5

  An enantioselective, catalytic trichloromethylation of 2-acyl imidazoles and 2-acylpyridines is reported. Several products are formed with enantiomeric excess of ≥99%. In this system, a chiral iridium complex serves a dual function, as a catalytically active chiral Lewis acid and simultaneously as a precursor for an in situ assembled visible-light-triggered photoredox catalyst.

  报道了 2-酰基咪唑和 2-酰基吡啶的对映选择性催化三氯甲基化。几种产品形成对映体过量≥99%。在该系统中，手性铱配合物具有双重功能，既作为具有催化活性的手性路易斯酸，又作为原位组装的可见光触发光氧化还原催化剂的前体。
• Alkyl sulfonamide derivatives
  申请人：Jubian Vrej

  公开号：US20060293341A1

  公开（公告）日：2006-12-28

  This invention is directed to alkyl sulfonamide derivatives which are ligands at the NPY Y5 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression which comprises administering to the subject an amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from anxiety which comprises administering to the subject an amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject an amount of a compound of the subject invention.

  这项发明涉及烷基磺胺基衍生物，其为NPY Y5受体的配体。该发明提供了一种包含该发明化合物的治疗有效量和药学上可接受的载体的药物组合物。该发明还提供了一种通过混合该发明化合物的治疗有效量和药学上可接受的载体制备的药物组合物。该发明还提供了一种制备药物组合物的方法，包括结合该发明化合物的治疗有效量和药学上可接受的载体。该发明还提供了一种治疗患有抑郁症的受试者的方法，包括向受试者施用该发明化合物的量。该发明还提供了一种治疗患有焦虑症的受试者的方法，包括向受试者施用该发明化合物的量。该发明还提供了一种治疗患有肥胖症的受试者的方法，包括向受试者施用该发明化合物的量。
• Novel 2-pyridinecarboxamide derivatives
  申请人：Mitsuya Morihiro

  公开号：US20060258701A1

  公开（公告）日：2006-11-16

  The present invention relates to a compound which has a glucokinase-activating effect and is useful as a therapeutic agent for diabetes mellitus, being represented by a formula (I): [wherein X 1 represents a nitrogen atom, sulfur atom, oxygen atom or the like; R 1 represents a 6- to 10-membered aryl group, 5- to 7-membered heteroaryl group or the like; D represents an oxygen atom or sulfur atom; R and R 3 are the same or different, each representing a hydrogen atom, lower alkyl group or the like; a formula (II) represents an optionally substituted 5- to 7-membered heteroaryl group or the like; a formula (III) represents a monocyclic or bicyclic heteroaryl group] or a pharmaceutically acceptable salt thereof.

  本发明涉及一种化合物，具有激活葡萄糖激酶的效果，并可用作糖尿病治疗剂，其化学式表示为（I）：[其中X1表示氮原子、硫原子、氧原子或类似物；R1表示6-至10-成员芳基基团、5-至7-成员杂芳基基团或类似物；D表示氧原子或硫原子；R和R3相同或不同，分别表示氢原子、低碳基或类似物；式（II）表示可选取代的5-至7-成员杂芳基团或类似物；式（III）表示单环或双环杂芳基团]或其药学上可接受的盐。
• NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES
  申请人：MITSUYA MORIHIRO

  公开号：US20100041660A1

  公开（公告）日：2010-02-18

  The present invention relates to a compound which has a glucokinase-activating effect and is useful as a therapeutic agent for diabetes mellitus, being represented by a formula (I): [wherein X 1 represents a nitrogen atom, sulfur atom, oxygen atom or the like; R 1 represents a 6- to 10-membered aryl group, 5- to 7-membered heteroaryl group or the like; D represents an oxygen atom or sulfur atom; R 2 and R 3 are the same or different, each representing a hydrogen atom, lower alkyl group or the like; a formula (II) represents an optionally substituted 5- to 7-membered heteroaryl group or the like; a formula (III) represents a monocyclic or bicyclic heteroaryl group] or a pharmaceutically acceptable salt thereof.

  本发明涉及一种具有葡萄糖激酶激活作用并且可用作糖尿病治疗剂的化合物，其化学式为（I）：[其中X1代表氮原子、硫原子、氧原子或类似物；R1代表6到10个成员的芳基基团、5到7个成员的杂芳基团或类似物；D代表氧原子或硫原子；R2和R3相同或不同，每个代表氢原子、低碳基团或类似物；化学式（II）代表可选取代的5到7个成员的杂芳基团或类似物；化学式（III）代表单环或双环杂芳基团]或其药学上可接受的盐。
• DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：US20140031334A1

  公开（公告）日：2014-01-30

  A heterocyclic compound or a salt thereof represented by the formula (1): where R 2 represents a hydrogen atom or a lower alkyl group; A represents a lower alkylene group or lower alkenylene group; and R 1 represents an aromatic group or a heterocyclic group. The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.

  一种由公式（1）表示的杂环化合物或其盐： 其中，R2表示氢原子或低级烷基基团；A表示低级烷基烯基基团；R1表示芳香基团或杂环基团。本发明的化合物具有广泛的治疗精神障碍，包括中枢神经系统障碍的光谱，无副作用和高安全性。